{"success":true,"data":{"pressRelease":{"id":"110752","rtpr_id":"nGNE5zxFQF","ticker":"INVP","exchange":"LSE","all_tickers":["INVP"],"title":"REG-Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc","author":"Globe Newswire","published_at":"2026-08-06T09:21:27.067Z","article_body":"FORM 8.5 (EPT/RI)\n\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED\nINTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY \nRule 8.5 of the Takeover Code (the “Code”)\n\n1.        KEY INFORMATION\n\n (a) Name of exempt principal trader: Investec Bank Plc \n (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Advanced Medical Solutions Group Plc \n (c) Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc \n (d) Date dealing undertaken: 05 (th)August 2026 \n (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A \n\n2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n\nWhere there have been dealings in more than one class of relevant securities\nof the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as\nappropriate) for each additional class of relevant security dealt in.\n\nThe currency of all prices and other monetary amounts should be stated.\n\n(a)        Purchases and sales\n\n Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received \n Ordinary shares Purchase 899,986 280.5 280.25 \n Ordinary shares Sales 924,119 281.25 280.5 \n\n(b)        Cash-settled derivative transactions\n\n Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit \n N/A N/A N/A N/A N/A \n\n(c)        Stock-settled derivative transactions (including options)\n\n(i)        Writing, selling, purchasing or varying\n\n Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit \n N/A N/A N/A N/A N/A N/A N/A N/A \n\n(ii)        Exercise\n\n Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit \n N/A N/A N/A N/A N/A \n\n(d)        Other dealings (including subscribing for new securities)\n\n Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) \n N/A N/A N/A N/A \n\n3.        OTHER INFORMATION\n\n(a)        Indemnity and other dealing arrangements\n\n Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” \n None \n\n(b)        Agreements, arrangements or understandings relating to\noptions or derivatives\n\n Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” \n None \n\n\n\n Date of disclosure: 06 (th)August 2026 \n Contact name: Abhishek Gawde \n Telephone number: +91-9923757332 \n\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory\nInformation Service.\n\nThe Panel’s Market Surveillance Unit is available for consultation in\nrelation to the Code’s dealing disclosure requirements on +44 (0)20 7638\n0129.\n\nThe Code can be viewed on the Panel’s website at\nssssssswwww.thetakeoverpanel.org.uk.","article_body_html":"","raw_payload":{"data":{"id":"nGNE5zxFQF","title":"REG-Form 8.5 (EPT/RI)-Advanced Medical Solutions Group Plc","author":"Globe Newswire","ticker":"INVP","created":"2026-08-06T09:21:27.067Z","tickers":["INVP"],"exchange":"LSE","article_body":"FORM 8.5 (EPT/RI)\n\nPUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED\nINTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY \nRule 8.5 of the Takeover Code (the “Code”)\n\n1.        KEY INFORMATION\n\n (a) Name of exempt principal trader: Investec Bank Plc \n (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Advanced Medical Solutions Group Plc \n (c) Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor & Joint Broker to Advanced Medical Solutions Group plc \n (d) Date dealing undertaken: 05 (th)August 2026 \n (e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer? If it is a cash offer or possible cash offer, state “N/A” N/A \n\n2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER\n\nWhere there have been dealings in more than one class of relevant securities\nof the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as\nappropriate) for each additional class of relevant security dealt in.\n\nThe currency of all prices and other monetary amounts should be stated.\n\n(a)        Purchases and sales\n\n Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received \n Ordinary shares Purchase 899,986 280.5 280.25 \n Ordinary shares Sales 924,119 281.25 280.5 \n\n(b)        Cash-settled derivative transactions\n\n Class of relevant security Product description e.g. CFD Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position Number of reference securities Price per unit \n N/A N/A N/A N/A N/A \n\n(c)        Stock-settled derivative transactions (including options)\n\n(i)        Writing, selling, purchasing or varying\n\n Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type e.g. American, European etc. Expiry date Option money paid/ received per unit \n N/A N/A N/A N/A N/A N/A N/A N/A \n\n(ii)        Exercise\n\n Class of relevant security Product description e.g. call option Exercising/ exercised against Number of securities Exercise price per unit \n N/A N/A N/A N/A N/A \n\n(d)        Other dealings (including subscribing for new securities)\n\n Class of relevant security Nature of dealing e.g. subscription, conversion Details Price per unit (if applicable) \n N/A N/A N/A N/A \n\n3.        OTHER INFORMATION\n\n(a)        Indemnity and other dealing arrangements\n\n Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” \n None \n\n(b)        Agreements, arrangements or understandings relating to\noptions or derivatives\n\n Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none” \n None \n\n\n\n Date of disclosure: 06 (th)August 2026 \n Contact name: Abhishek Gawde \n Telephone number: +91-9923757332 \n\nPublic disclosures under Rule 8 of the Code must be made to a Regulatory\nInformation Service.\n\nThe Panel’s Market Surveillance Unit is available for consultation in\nrelation to the Code’s dealing disclosure requirements on +44 (0)20 7638\n0129.\n\nThe Code can be viewed on the Panel’s website at\nssssssswwww.thetakeoverpanel.org.uk."},"type":"article","timestamp":"2026-08-06T09:21:33.619488115Z","server_sent_at_ms":1786008093619},"received_at":"2026-08-06T09:21:33.669Z","source_url":null},"analysis":{"id":"99755","press_release_id":"110752","analysis_json":{"industry":{"label":"Capital Markets","sector":"Financials"},"redFlags":[],"eventType":"insider_transaction","narrative":"Investec Bank Plc filed a Form 8.5 disclosure regarding its dealings as an exempt principal trader in the ordinary shares of Advanced Medical Solutions Group Plc.\n\nThe transactions, undertaken on August 5, 2026, while Investec acted as Advisor & Joint Broker, involved the purchase of 899,986 shares and the sale of 924,119 shares.\n\nPrices per share ranged from 280.25p to 281.25p, with no cash-settled or stock-settled derivative transactions reported.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine regulatory disclosure of client-servicing trades."},"keyFigures":{"customDimensions":{"currency":"pence (implied)","shares_sold":924119,"sale_price_low":280.5,"sale_price_high":281.25,"shares_purchased":899986,"purchase_price_low":280.25,"purchase_price_high":280.5}},"quotedText":"","namedEntities":{"people":[{"name":"Abhishek Gawde","role":"Contact"}],"products":["Ordinary shares"],"companies":[{"name":"Investec Bank Plc","relationship":"exempt principal trader / advisor"},{"name":"Advanced Medical Solutions Group Plc","relationship":"offeror/offeree / client"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine Form 8.5 disclosure by an exempt principal trader regarding client-servicing capacity transactions. The trading volume is balanced and represents standard market-making or advisory facilitation rather than a directional bet by the bank."},"tickerRelevance":{"others":[],"primary":"INVP"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid_cap","eventGravity":"routine_regulatory_disclosure","issuerAuthored":true}},"event_type":"insider_transaction","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Investec Bank Plc filed a Form 8.5 disclosure regarding its dealings as an exempt principal trader in the ordinary shares of Advanced Medical Solutions Group Plc.\n\nThe transactions, undertaken on August 5, 2026, while Investec acted as Advisor & Joint Broker, involved the purchase of 899,986 shares and the sale of 924,119 shares.\n\nPrices per share ranged from 280.25p to 281.25p, with no cash-settled or stock-settled derivative transactions reported.","key_figures":{"customDimensions":{"currency":"pence (implied)","shares_sold":924119,"sale_price_low":280.5,"sale_price_high":281.25,"shares_purchased":899986,"purchase_price_low":280.25,"purchase_price_high":280.5}},"named_entities":{"people":[{"name":"Abhishek Gawde","role":"Contact"}],"products":["Ordinary shares"],"companies":[{"name":"Investec Bank Plc","relationship":"exempt principal trader / advisor"},{"name":"Advanced Medical Solutions Group Plc","relationship":"offeror/offeree / client"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-06T10:54:26.882Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"mid_cap","eventGravity":"routine_regulatory_disclosure","issuerAuthored":true}},"durationMs":303874,"modelName":"glm-4.7"}}